These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33061420)

  • 1. Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies.
    Lu Q; Chen X; Wang S; Lu Y; Yang C; Jiang G
    Onco Targets Ther; 2020; 13():9323-9331. PubMed ID: 33061420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Cancer Sci; 2018 Aug; 109(8):2349-2357. PubMed ID: 29873856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
    Zhang J; Jin S; Guo X; Qian W
    J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
    van Helden MJ; Zwarthoff SA; Arends RJ; Reinieren-Beeren IMJ; Paradé MCBC; Driessen-Engels L; de Laat-Arts K; Damming D; Santegoeds-Lenssen EWH; van Kuppeveld DWJ; Lodewijks I; Olsman H; Matlung HL; Franke K; Mattaar-Hepp E; Stokman MEM; de Wit B; Glaudemans DHRF; van Wijk DEJW; Joosten-Stoffels L; Schouten J; Boersema PJ; van der Vleuten M; Sanderink JWH; Kappers WA; van den Dobbelsteen D; Timmers M; Ubink R; Rouwendal GJA; Verheijden G; van der Lee MMC; Dokter WHA; van den Berg TK
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37068796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells.
    Ko YJ; Lee JW; Kim H; Cho E; Yang Y; Kim IS; Kim SH; Kwon IC
    J Control Release; 2020 Jul; 323():376-386. PubMed ID: 32335154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding Mechanism of CD47 with SIRPα Variants and Its Antibody: Elucidated by Molecular Dynamics Simulations.
    Huang K; Liu Y; Wen S; Zhao Y; Ding H; Liu H; Kong DX
    Molecules; 2023 Jun; 28(12):. PubMed ID: 37375166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
    Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
    MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CD47-SIRPα signalling system: its physiological roles and therapeutic application.
    Murata Y; Kotani T; Ohnishi H; Matozaki T
    J Biochem; 2014 Jun; 155(6):335-44. PubMed ID: 24627525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed.
    Qu T; Li B; Wang Y
    Biomark Res; 2022 Apr; 10(1):20. PubMed ID: 35418166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Latest Findings on the Role of CD47 in Tumor Immune Evasion and Related Targeted Therapies].
    Jie XL; Kong YY; Zhou GB
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):455-461. PubMed ID: 37248568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy.
    Liu J; Xavy S; Mihardja S; Chen S; Sompalli K; Feng D; Choi T; Agoram B; Majeti R; Weissman IL; Volkmer JP
    JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32427583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience.
    Folkes AS; Feng M; Zain JM; Abdulla F; Rosen ST; Querfeld C
    Curr Opin Oncol; 2018 Sep; 30(5):332-337. PubMed ID: 29994903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice.
    Abe T; Tanaka Y; Piao J; Tanimine N; Oue N; Hinoi T; Garcia NV; Miyasaka M; Matozaki T; Yasui W; Ohdan H
    Ann Gastroenterol Surg; 2018 Nov; 2(6):451-462. PubMed ID: 30460349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Therapy Targeting CD47/SIRPα.
    Dizman N; Buchbinder EI
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.